Flow Neuroscience is now available by prescription across the United States.

At Flow Neuroscience, we are redefining the treatment of Major Depressive Disorder through innovations at the intersection of neuromodulation and patient-led care. As the creators of the first and only FDA-approved, at-home, first-line tDCS treatment for depression, we design mental healthcare solutions that are highly tolerable and designed for the patient's daily life. By combining a pivotal RCT published in Nature Medicine with extensive Real-World Evidence (RWE) from over 60,000 patients, we are developing the next generation of mental health solutions. Our technology is engineered to tackle the most pervasive challenges in psychiatry, offering an approach that delivers clinical efficacy with a favorable side-effect profile and next-level convenience. We are committed to making evidence-based, clinical-grade brain stimulation accessible to people around the world, whether as a standalone intervention or an adjunct to existing care. Visit for more information: flowneuroscience.com

Founded 2016